Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.

Aliment Pharmacol Ther · 2017 · PMC5434950 · PMID 28370090

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Overall survival at day 90 was significantly lower in females than in males; however, females receiving terlipressin showed a trend towards improved survival compared with those receiving placebo, and the survival estimate was similar to that for males.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.